Roche first-quarter sales up

Roche expects "mid to high" single digit growth to continue in 2002 Keystone

Pharmaceutical group Roche has announced a six per cent rise in first-quarter sales to SFr7.37 billion.

This content was published on April 16, 2002 - 09:45

The company expects mid to high single digit growth to continue for the remainder of the year.

Sales in Roche's drug division rose five percent, when expressed in Swiss francs, while its diagnostics businesses yielded 9 percent.

Franz Humer, Roche's CEO, rejected speculation that the company was preparing a merger with drug giant Novartis.

swissinfo with agencies

This article was automatically imported from our old content management system. If you see any display errors, please let us know:

Comments under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Share this story

Join the conversation!

With a SWI account, you have the opportunity to contribute on our website.

You can Login or register here.